
    
      A Phase I, Randomised, Open-label, 3 way Cross-over Study in Healthy Volunteers to
      Demonstrate the Bioequivalence of the Naloxegol 25 mg Commercial and Phase III Formulations
      and to Assess the Effect of Food Administration on the Pharmacokinetics of the Commercial
      Formulation.
    
  